Archives: 2020-01-17

PIER MARIA FORNASARI
2020-01-17

The Lancet Digital Health: Real-time flu prediction may be possible using wearable heart rate and sleep tracking devices

First study to evaluate de-identified data from wearable devices on resting heart rate and sleep finds improved real-time prediction of influenza-like illness in 5 US states compared to current surveillance methods The research, published in The Lancet Digital Health journal, demonstrates the potential of data from wearable devices to improve surveillance of infectious disease. Resting heart rate

Read More

No Comments InDIGITAL HEALTH
PIER MARIA FORNASARI
2020-01-17

New Microscopy Technique Shows Cells’ 3-D Ultrastructure in New Detail

The method melds the best of super-resolution fluorescence and electron microscopy to show how proteins relate to cells’ fine structure. Inside a cell, tentacled vesicles shuttle cargo for sorting. Neighboring neurons cling to one another through a web-like interface. DNA rearranges in the nucleus as stem cells differentiate into neurons. And a new microscopy technique

Read More

No Comments InRESEARCH
PIER MARIA FORNASARI
2020-01-16

Why stem cells could be the medical innovation of the century for World Economic Forum

Source World Economic Forum The current market for stem cell therapies is growing at 36% per year and will rapidly expand when a breakthrough treatment for non-communicable disease or a lifestyle factor occurs. Funding is flowing into the sector from venture capitalists and large companies. With greater resources and an increasingly experienced talent pool, scientists

Read More

No Comments InREGENERATIVE MEDICINE
PIER MARIA FORNASARI
2020-01-15

UK accounts for over 12% of global cell and gene therapy clinical trials. CGT Catapult new report

The UK and the NHS are providing the right environment and infrastructure to allow innovative cell and gene therapies to reach patients. International companies recognise the appeal of the UK cell and gene therapy ecosystem and are sponsoring the majority of the UK commercial clinical trials which account for 77% of the total 127 ongoing trials.

Read More

No Comments InGENE THERAPY RARE DISEASES
PIER MARIA FORNASARI
2020-01-13

bluebird bio Announces Launch in Germany of ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia Who Do Not Have β0/β0 Genotype

First agreements with statutory health insurances utilize bluebird’s innovative value-based payment model and provide coverage for ZYNTEGLO for up to 50% of patients in Germany First qualified treatment center established at University Hospital of Heidelberg to provide ZYNTEGLO to patients  bluebird bio, Inc. announced the launch in Germany of ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene), a

Read More

No Comments InGENE THERAPY RARE DISEASES
PIER MARIA FORNASARI
2020-01-10

The Alliance for Regenerative Medicine Demonstrates Potential for Cell and Gene Therapies to Provide 10-Year Cost Savings to the Healthcare System

ARM today announced the release of a report, “A Transformative Therapy Value Model for Rare Blood Diseases.” The report uses a refined value model to assess the impact of durable and potentially curative cell and gene therapies on health system costs.   Produced in collaboration with the Marwood Institute, this report calculates the potential cost savings that

Read More

No Comments InGENE THERAPY RARE DISEASES
PIER MARIA FORNASARI
2020-01-10

Nanoparticles deliver ‘suicide gene’ therapy to pediatric brain tumors growing in mice

Johns Hopkins researchers report that a type of biodegradable, lab-engineered nanoparticle they fashioned can successfully deliver a “suicide gene” to pediatric brain tumor cells implanted in the brains of mice. The poly(beta-amino ester) nanoparticles, known as PBAEs, were part of a treatment that also used a drug to kill the cells and prolong the test

Read More

No Comments InCANCER GENE THERAPY RARE DISEASES